Patents by Inventor Gary J. Wiley
Gary J. Wiley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969578Abstract: Methods, devices and systems are disclosed for inter-app communications between software applications on a mobile communications device. In one aspect, a computer-readable medium on a mobile computing device comprising an inter-application communication data structure to facilitate transitioning and distributing data between software applications in a shared app group for an operating system of the mobile computing device includes a scheme field of the data structure providing a scheme id associated with a target software app to transition to from a source software app, wherein the scheme id is listed on a scheme list stored with the source software app; and a payload field of the data structure providing data and/or an identification where to access data in a shared file system accessible to the software applications in the shared app group, wherein the payload field is encrypted.Type: GrantFiled: March 16, 2021Date of Patent: April 30, 2024Assignee: Dexcom, Inc.Inventors: Gary A. Morris, Scott M. Belliveau, Esteban Cabrera, Jr., Rian Draeger, Laura J. Dunn, Timothy Joseph Goldsmith, Hari Hampapuram, Christopher Robert Hannemann, Apurv Ullas Kamath, Katherine Yerre Koehler, Patrick Wile McBride, Michael Robert Mensinger, Francis William Pascual, Philip Mansiel Pellouchoud, Nicholas Polytaridis, Philip Thomas Pupa, Anna Leigh Davis, Kevin Shoemaker, Brian Christopher Smith, Benjamin Elrod West, Atiim Joseph Wiley
-
Publication number: 20240091442Abstract: Methods, devices and systems are disclosed for inter-app communications between software applications on a mobile communications device. In one aspect, a computer-readable medium on a mobile computing device comprising an inter-application communication data structure to facilitate transitioning and distributing data between software applications in a shared app group for an operating system of the mobile computing device includes a scheme field of the data structure providing a scheme id associated with a target software app to transition to from a source software app, wherein the scheme id is listed on a scheme list stored with the source software app; and a payload field of the data structure providing data and/or an identification where to access data in a shared file system accessible to the software applications in the shared app group, wherein the payload field is encrypted.Type: ApplicationFiled: September 27, 2023Publication date: March 21, 2024Inventors: Gary A. MORRIS, Scott M. BELLIVEAU, Esteban CABRERA, JR., Anna Leigh DAVIS, Rian W. DRAEGER, Laura J. DUNN, Timothy Joseph GOLDSMITH, Hari HAMPAPURAM, Christopher Robert HANNEMANN, Apurv Ullas KAMATH, Katherine Yerre KOEHLER, Patrick Wile MCBRIDE, Michael Robert MENSINGER, Francis William PASCUAL, Philip Mansiel PELLOUCHOUD, Nicholas POLYTARIDIS, Philip Thomas PUPA, Kevin SHOEMAKER, Brian Christopher SMITH, Benjamin Elrod WEST, Atiim Joseph WILEY
-
Publication number: 20240071593Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.Type: ApplicationFiled: October 24, 2023Publication date: February 29, 2024Inventors: Anna Leigh DAVIS, Scott M. BELLIVEAU, Naresh C. BHAVARAJU, Leif N. BOWMAN, Rita M. CASTILLO, Alexandra Elena CONSTANTIN, Rian W. DRAEGER, Laura J. DUNN, Gary Brian GABLE, Arturo GARCIA, Thomas HALL, Hari HAMPAPURAM, Christopher Robert HANNEMANN, Anna Claire HARLEY-TROCHIMCZYK, Nathaniel David HEINTZMAN, Andrea Jean JACKSON, Lauren Hruby JEPSON, Apurv Ullas KAMATH, Katherine Yerre KOEHLER, Aditya Sagar MANDAPAKA, Samuel Jere MARSH, Gary A. MORRIS, Subrai Girish PAI, Andrew Attila PAL, Nicholas POLYTARIDIS, Philip Thomas PUPA, Eli REIHMAN, Ashley Anne RINDFLEISCH, Sofie Wells SCHUNK, Peter C. SIMPSON, Daniel S. SMITH, Stephen J. VANSLYKE, Matthew T. VOGEL, Tomas C. WALKER, Benjamin Elrod WEST, Atiim Joseph WILEY
-
Patent number: 7175856Abstract: A drug formulation in the form of a dry powder is provided which when mixed with water forms a palatable oral suspension substantially free of bitter taste, the dry powder being formed of a drug, preferably des-quinolone, which in solution has a bitter taste, and a pH modifying agent which is preferably an alkaline material such as L-arginine, where upon mixing the dry-powder in water causes the drug to have reduced solubility or precipitate in-situ to form a palatable oral suspension essentially free of bitter taste. An oral suspension, methods for making same and a method for masking the bitter taste of drugs employing one or more pH modifying agents are also provided.Type: GrantFiled: March 11, 2003Date of Patent: February 13, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J. Wiley
-
Patent number: 7122207Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.Type: GrantFiled: May 3, 2001Date of Patent: October 17, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J Wiley
-
Publication number: 20030187019Abstract: A drug formulation in the form of a dry powder is provided which when mixed with water forms a palatable oral suspension substantially free of bitter taste, the dry powder being formed of a drug, preferably des-quinolone, which in solution has a bitter taste, and a pH modifying agent which is preferably an alkaline material such as L-arginine, where upon mixing the dry-powder in water causes the drug to have reduced solubility or precipitate in-situ to form a palatable oral suspension essentially free of bitter taste.Type: ApplicationFiled: March 11, 2003Publication date: October 2, 2003Inventors: Ismat Ullah, Gary J. Wiley
-
Patent number: 6607747Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.Type: GrantFiled: November 16, 2001Date of Patent: August 19, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J Wiley
-
Patent number: 6569457Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a plasticizer. The tablets may be of varying sizes and may be orally ingested individually or a plurality of tablets sufficient to attain a desired dosage may be encapsulated in a dissolvable capsule. The tablets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.Type: GrantFiled: May 25, 2001Date of Patent: May 27, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J. Wiley
-
Publication number: 20020076438Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.Type: ApplicationFiled: November 16, 2001Publication date: June 20, 2002Inventors: Ismat Ullah, Gary J. Wiley
-
Publication number: 20020051818Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a plasticizer. The tablets may be of varying sizes and may be orally ingested individually or a plurality of tablets sufficient to attain a desired dosage may be encapsulated in a dissolvable capsule. The tablets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.Type: ApplicationFiled: May 25, 2001Publication date: May 2, 2002Inventors: Ismat Ullah, Gary J. Wiley
-
Patent number: 6331316Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a plasticizer. The tablets may be of varying sizes and may be orally ingested individually or a plurality of tablets sufficient to attain a desired dosage may be encapsulated in a dissolvable capsule. The tablets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.Type: GrantFiled: April 14, 2000Date of Patent: December 18, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J. Wiley
-
Publication number: 20010051188Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.Type: ApplicationFiled: May 3, 2001Publication date: December 13, 2001Inventors: Ismat Ullah, Gary J. Wiley
-
Publication number: 20010024660Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, which composition is preferably in the form of beadlets having an enteric coating formed of methacrylic acid copolymer, plasticizer and an additional coat comprising an anti-adherent. The so-called beadlets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.Type: ApplicationFiled: December 12, 2000Publication date: September 27, 2001Inventors: Ismat Ullah, Gary J. Wiley
-
Publication number: 20010005716Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, which composition is preferably in the form of beadlets having an enteric coating formed of methacrylic acid copolymer, plasticizer and an additional coat comprising an anti-adherent. The so-called beadlets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.Type: ApplicationFiled: January 16, 2001Publication date: June 28, 2001Inventors: Ismat Ullah, Gary J. Wiley
-
Patent number: 6224910Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, which composition is preferably in the form of beadlets having an enteric coating formed of methacrylic acid copolymer, plasticizer and an additional coat comprising an anti-adherent. The so-called beadlets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.Type: GrantFiled: September 29, 1999Date of Patent: May 1, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Ismat Ullah, Gary J. Wiley